Trials / Completed
CompletedNCT03897868
A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension
A Muticenter, Randomized, Double-blind, Parallel, Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 248 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter, randomized, double-blind, parallel, phase 2 study to assess dose-response relationship of HCP1803 in patients with essential hypertension
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HCP1803 | HCP1803 |
| DRUG | Amlodipine | Amlodipine |
| DRUG | Losartan | Losartan |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2019-03-21
- Primary completion
- 2020-02-26
- Completion
- 2020-02-26
- First posted
- 2019-04-01
- Last updated
- 2022-07-14
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03897868. Inclusion in this directory is not an endorsement.